nach oben

Erschienen in:

06.12.2019 | Review Article

Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management

verfasst von: Michele Correale, Lucia Tricarico, Davide Grazioli, Ennio Sascia Formica, Rossella Petrucci, Paola Persichella, Matteo Di Biase, Natale Daniele Brunetti

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Pulmonary arterial hypertension is a rare disease, with drug-induced causes even more uncommon, accounting for only 10% of cases in large registry series. Predisposing factors for drug-induced PAH have not been completely defined. This review summarizes drugs with definite, possible, or likely association to pulmonary hypertension and possible mechanisms involved in the occurrence of pulmonary hypertension. Controversies on mechanisms and on their role in pathophysiology were also shown. The possible synergism between drug abuse and HIV was discussed and the possible interactions of antiretroviral therapy in HIV subjects were analyzed. Furthermore, we reported clinical findings and possible management, specific for each class of drugs, in case of drug-induced PAH. Finally, we summarized into a unified algorithm possible management of drug-induced PAH.

Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46:903–75.PubMed

Gurtner HP. Aminorex and pulmonary hypertension. A review Cor Vasa. 1985;27:160–71.PubMed

Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137:376–87.PubMed

Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest. 2012;142:448–56.PubMed

Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019;53. pii: 1801913.PubMed

Vinicio A. de Jesus Perez. Drug-induced pulmonary hypertension: the first 50 years. Advances in Pulmonary Hypertension 2017;15:133–137.

MacLean MMR. The serotonin hypothesis in pulmonary hypertension revisited: targets for novel therapies (2017 Grover Conference Series). Pulm Circ. 2018;8(2):2045894018759125.PubMed

Hood KY, Mair KM, Harvey AP, Montezano AC, Touyz RM, MacLean MR. Serotonin signaling through the 5-HT1B receptor and NADPH oxidase 1 in pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2017;37:1361–70.PubMedPubMedCentral

Maclean MR, Dempsie Y. The serotonin hypothesis of pulmonary hypertension revisited. Adv Exp Med Biol. 2010;661:309–22.PubMed

10.

Pleym H, Greiff G, Mjorndal T, Stenseth R, Wahba A, Spigset O. Effect of serotonin reuptake inhibitors on pulmonary hemodynamics in humans. J Clin Med Res. 2011;3:230–8.PubMedPubMedCentral

11.

Guignabert C, Izikki M, Tu LI, Li Z, Zadigue P, Barlier-Mur AM, et al. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res. 2006;98:1323–30.PubMed

12.

Adnot S, Houssaini A, Abid S, Marcos E, Amsellem V. Serotonin transporter and serotonin receptors. Handb Exp Pharmacol. 2013;218:365–80.PubMed

13.

Dempsie Y, MacLean MMR. Role of the serotonin transporter in pulmonary arterial hypertension. Expert Rev Clin Pharmacol. 2008;1:749–57.PubMed

14.

Eddahibi S, Adnot S. Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis. Respir Res. 2001;3:9.PubMedPubMedCentral

15.

MacLean MR. Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action? Trends Pharmacol Sci. 1999;20:490–5.PubMed

16.

Dempsie Y, Morecroft I, Welsh DJ, MacRitchie NA, Herold N, Loughlin L, et al. Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice. Circulation. 2008;117:2928–37.PubMed

17.

Nagy BM, Nagaraj C, Meinitzer A, Sharma N, Papp R, Foris V, et al. Importance of kynurenine in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2017;313:L741–51.PubMed

18.

Chen PI, Cao A, Miyagawa K, Tojais NF, Hennigs JK, Li CG, et al. Amphetamines promote mitochondrial dysfunction and DNA damage in pulmonary hypertension. JCI Insight. 2017;2:e90427.PubMedPubMedCentral

19.

Ranchoux B, Meloche J, Paulin R, Boucherat O, Provencher S, Bonnet S. DNA damage and pulmonary hypertension. Int J Mol Sci. 2016;17(6).PubMedCentral

20.

Brown JM, Yamamoto BK. Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress. Pharmacol Ther. 2003;99:45–53.PubMed

21.

Tseng YP, Padbury J. Expression of a pulmonary endothelial norepinephrine transporter. J Neural Transm. 1998;105:1187–91.PubMed

22.

Salvi SS. Alpha1-adrenergic hypothesis for pulmonary hypertension. Chest. 1999;115:1708–19.PubMed

23.

Orcholski ME, Khurshudyan A, Shamskhou EA, Yuan K, Chen IY, Kodani SD, et al. Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-induced pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2017;313:L252–66.PubMedPubMedCentral

24.

Montani D, Seferian A, Savale L, Simonneau G, Humbert M. Drug-induced pulmonary arterial hypertension: a recent outbreak. Eur Respir Rev. 2013;22:244–50.PubMed

25.

Savale L, Chaumais MC, Cottin V, Bergot E, Frachon I, Prevot G, et al. Pulmonary hypertension associated with benfluorex exposure. Eur Respir J. 2012;40:1164–72.PubMed

26.

Hendricks-Munoz KD, Gerrets RP, Higgins RD, Munoz JL, Caines VV. Cocaine-stimulated endothelin-1 release is decreased by angiotensin-converting enzyme inhibitors in cultured endothelial cells. Cardiovasc Res. 1996;31:117–23.PubMed

27.

Pradhan L, Mondal D, Chandra S, Ali M, Agrawal KC. Molecular analysis of cocaine-induced endothelial dysfunction: role of endothelin-1 and nitric oxide. Cardiovasc Toxicol. 2008;8:161–71.PubMed

28.

Robertson CH Jr, Reynolds RC, Wilson JE 3rd. Pulmonary hypertension and foreign body granulomas in intravenous drug abusers. Documentation by cardiac catheterization and lung biopsy. Am J Med. 1976;61:657–64.PubMed

29.

Tomashefski JF Jr, Hirsch CS. The pulmonary vascular lesions of intravenous drug abuse. Hum Pathol. 1980;11:133–45.PubMed

30.

Herculiani PP, Pires-Neto RC, Bueno HM, Zorzetto JC, Silva LC, Santos AB, et al. Effects of chronic exposure to crack cocaine on the respiratory tract of mice. Toxicol Pathol. 2009;37:324–32.PubMed

31.

Riezzo I, Fiore C, De Carlo D, Pascale N, Neri M, Turillazzi E, et al. Side effects of cocaine abuse: multiorgan toxicity and pathological consequences. Curr Med Chem. 2012;19:5624–46.PubMed

32.

Mehta PM, Grainger TA, Lust RM, Movahed A, Terry J, Gilliland MG, et al. Effect of cocaine on left ventricular function. Relation to increased wall stress and persistence after treatment. Circulation. 1995;91:3002–9.PubMed

33.

Pitts WR, Vongpatanasin W, Cigarroa JE, Hillis LD, Lange RA. Effects of the intracoronary infusion of cocaine on left ventricular systolic and diastolic function in humans. Circulation. 1998;97:1270–3.PubMed

34.

Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425–36.PubMed

35.

Opravil M, Pechère M, Speich R, Joller-Jemelka HI, Jenni R, Russi EW, et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med. 1997;155:990–5.PubMed

36.

Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43:5S–12S.PubMed

37.

Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023–30.PubMed

38.

Kanmogne GD, Kennedy RC, Grammas P. Analysis of human lung endothelialcells for susceptibility to HIV type 1 infection, coreceptor expression, and cytotoxicity of gp120 protein. AIDS Res Hum Retrovir. 2001;17:45–53.PubMed

39.

Almodovar S, Hsue PY, Morelli J, Huang L, Flores SC; Lung HIV Study. Pulmonary hypertension potential role of HIV-1 nef. HIV Study Proc Am Thorac Soc 2011;8:308–312.

40.

Correale M, Palmiotti GA, Lo Storto MM, Montrone D, Foschino Barbaro MP, Di Biase M, et al. HIV-associated pulmonary arterial hypertension: from bedside to the future. Eur J Clin Investig. 2015;45:515–28.

41.

Dhillon NK, Li F, Xue B, Tawfik O, Morgello S, Buch S, et al. Effect of cocaine on human immunodeficiency virus-mediated pulmonary endothelial and smooth muscle dysfunction. Am J Respir Cell MolBiol. 2001;45:40–52.

42.

Dalvi P, Wang K, Mermis J, Zeng R, Sanderson M, Johnson S, et al. HIV-1/cocaine induced oxidative stress disrupts tight junction protein-1 in human pulmonary microvascular endothelial cells: role of Ras/ERK1/2 pathway. PLoS One. 2014 Jan 7;9:e85246.PubMedPubMedCentral

43.

Dalvi P, O'Brien-Ladner A, Dhillon NK. Downregulation of bone morphogenetic protein receptor axis during HIV-1 and cocaine-mediated pulmonary smooth muscle hyperplasia: implications for HIV-related pulmonary arterial hypertension. Arterioscler Thromb VascBiol. 2013;33:2585–95.

44.

Dalvi P, Spikes L, Allen J, Gupta VG, Sharma H, Gillcrist M, et al. Effect of cocaine on pulmonary vascular remodeling and hemodynamics in human immunodeficiency virus-transgenic rats. Am J Respir Cell Mol Biol. 2016;55:201–12.PubMedPubMedCentral

45.

Spikes L, Dalvi P, Tawfik O, Gu H, Voelkel NF, Cheney P, et al. Enhanced pulmonary arteriopathy in simian immunodeficiency virus-infected macaques exposed to morphine. Am J Respir Crit Care Med. 2012;185:1235–43.PubMedPubMedCentral

46.

Dalvi P, Sharma H, Chinnappan M, Sanderson M, Allen J, Zeng R, et al. Enhanced autophagy in pulmonary endothelial cells on exposure to HIV-Tat and morphine: role in HIV-related pulmonary arterial hypertension. Autophagy. 2016;12:2420–38.PubMedPubMedCentral

47.

Martinez EA, Hartsfield SM, Melendez LD, Matthews NS, Slater MR. Cardiovascular effects of buprenorphine in anesthetized dogs. Am J Vet Res. 1997;58:1280–4.PubMed

48.

Sganzerla P, Cipolla C, Della Bella P, Fabbiocchi F, Grazi S, Rimondini A, et al. Analgesic and hemodynamic effects of buprenorphine in acute infarction of the heart. Jpn Heart J. 1987;28:63–71.PubMed

49.

Ho RC, Ho EC, Tan CH, Mak A. Pulmonary hypertension in first episode infective endocarditis among intravenous buprenorphine users: case report. Am J Drug Alcohol Abuse. 2009;35:199–202.PubMed

50.

Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest. 2000;117:870–4.PubMed

51.

Barst RJ, Abenhaim L. Fatal pulmonary arterial hypertension associated with phenylpropanolamine exposure. Heart. 2004;90:e42.PubMedPubMedCentral

52.

Ledinek AH, Jazbec SS, Drinovec I, Rot U. Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report. Mult Scler. 2009;15:885–6.PubMed

53.

Modrego PJ, Gazulla J. Arterial hypertension induced by interferon beta 1b in a patient with multiple sclerosis. Mult Scler. 2012;18:1655–6.PubMed

54.

Fok A, Williams T, McLean CA, Butler E. Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients. Mult Scler. 2016;22:1495–8.PubMed

55.

Savale L, Chaumais MC, O'Connell C, Humbert M, Sitbon O. Interferon-induced pulmonary hypertension: an update. Curr Opin Pulm Med. 2016;22:415–20.PubMed

56.

George PM, Cunningham ME, Galloway-Phillipps N, Badiger R, Alazawi W, Foster GR, et al. Endothelin-1 as a mediator and potential biomarker for interferon induced pulmonary toxicity. Pulm Circ. 2012;2:501–4.PubMedPubMedCentral

57.

Gibbons E, Promislow S, Davies RA, Chandy G, Stewart DJ, Vladamir CD, et al. Reversible pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis. Can Respir J. 2015;22:263–5.PubMedPubMedCentral

58.

George PM, Oliver E, Dorfmuller P, Dubois OD, Reed DM, Kirkby NS, et al. Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res. 2014;114:677–88.PubMed

59.

Tsuchiya H, Kioka H, Ozu K, Ohtani T, Yamaguchi O, Yazaki Y, et al. Interferon therapy exacerbated pulmonary hypertension in a patient with hepatitis C virus infection: pathogenic interplay among multiple risk factors. Intern Med. 2017;56:1061–5.PubMedPubMedCentral

60.

Nakano M, Fujii T, Hashimoto M, Yukawa N, Yoshifuji H, Ohmura K, et al. Type I interferon induces CX3CL1 (fractalkine) and CCL5 (RANTES) production in human pulmonary vascular endothelial cells. Clin Exp Immunol. 2012;170:94–100.PubMedPubMedCentral

61.

Papani R, Duarte AG, Lin YL, Kuo YF, Sharma G. Pulmonary arterial hypertension associated with interferon therapy: a population-based study. Multidisciplinary Respiratory Medicine. 2017;12:1.PubMedPubMedCentral

62.

Jose A, Rafei H, Ahari J. Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib-associated pulmonary arterial hypertension. Pulm Circ. 2017;7:803–7.PubMedPubMedCentral

63.

Riou M, Seferian A, Savale L, Chaumais MC, Guignabert C, Canuet M, et al. Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. Eur Respir J. 2016;48:1517–9.PubMed

64.

Moslehi JJ, Deininger M. Tyrosine kinase inhibitor–associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;35:4210–8.

65.

Minami M, Arita T, Iwasaki H, Muta T, Aoki T, Aoki K, et al. Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib. Br J Haematol. 2017;177:578–87.PubMed

66.

Hickey PM, Thompson AAR, Charalampopoulos A, Elliot CA, Hamilton N, Kiely DG, et al. Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension. Eur Respir J. 2016;48:1514–6.PubMed

67.

Groeneveldt JA, Gans SJ, Bogaard HJ, Vonk-Noordegraaf A. Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition. Eur Respir J. 2013;42:869–70.PubMed

68.

Pullamsetti SS, Berghausen EM, Dabral S, Tretyn A, Butrous E, Savai R, et al. Role of Src tyrosine kinases in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2012;32:1354–65.PubMed

69.

Ryan JJ. Tyrosine kinase inhibitors in pulmonary vascular disease. JACC: Basic to Translational Science. 2016;1:684–6.PubMed

70.

Baumgart B, Guha M, Hennan J, Li J, Woicke J, Simic D, et al. In vitro and in vivo evaluation of dasatinib and imatinib on physiological parameters of pulmonary arterial hypertension. Cancer Chemother Pharmacol. 2017;79:711–23.PubMed

71.

Guignabert C, Phan C, Seferian A, Huertas A, Tu L, Thuillet R, et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest. 2016;126:3207–18.PubMedPubMedCentral

72.

Phan C, Jutant EM, Tu L, Thuillet R, Seferian A, Montani D, et al. Dasatinib increases endothelial permeability leading to pleural effusion. Eur Respir J. 2018;51. pii: 1701096.PubMed

73.

Özgür Yurttaş N, Eşkazan AE. Dasatinib-induced pulmonary arterial hypertension. Br J Clin Pharmacol. 2018;84:835–45.PubMedPubMedCentral

74.

Cornet L, Khouri C, Roustit M, Guignabert C, Chaumais MC, Humbert M, et al. Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study. Eur Respir J. 2019;53. pii: 1802472.PubMed

75.

Renard S, Borentain P, Salaun E, Benhaourech S, Maille B, Darque A, et al. Severe pulmonary arterial hypertension in patients treated for hepatitis C with Sofosbuvir. Chest. 2016;149:e69–73.PubMed

76.

Garg L, Akbar G, Agrawal S, Agarwal M, Khaddour L, Handa R, et al. Drug-induced pulmonary arterial hypertension: a review. Heart Fail Rev. 2017;22:289–97.PubMed

77.

Rahbar R, Shapshay SM, Healy GB. Mitomycin: effects on laryngeal and tracheal stenosis, benefits, and complications. Ann Otol Rhinol Laryngol. 2001;110:1–6.PubMed

78.

Hoorn CM, Wagner JG, Petry TW, Roth RA. Toxicity of mitomycin C toward cultured pulmonary artery endothelium. Toxicol Appl Pharmacol. 1995;130:87–94.PubMed

79.

Joselson R, Warnock M. Pulmonary veno-occlusive disease after chemotherapy. Hum Pathol. 1983;14:88–91.PubMed

80.

Wu KY, Wang HZ, Hong SJ. Mechanism of mitomycin-induced apoptosis in cultured corneal endothelial cells. Mol Vis. 2008;14:1705–12.PubMedPubMedCentral

81.

Su C, Sui T, Zhang X, Zhang H, Cao X. Effect of topical application of mitomycin-C on wound healing in a postlaminectomy rat model: an experimental study. Eur J Pharmacol. 2012;674:7–12.PubMed

82.

Montani D, Lau EM, Descatha A, Jaïs X, Savale L, Andujar P, et al. Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. Eur Respir J. 2015;46:1721–31.PubMed

83.

Dhalla IA, Juurlink DN, Gomes T, Granton JT, Zheng H, Mamdani MM. Selective serotonin reuptake inhibitors and pulmonary arterial hypertension: a case-control study. Chest. 2012;141:348–53.PubMed

84.

Grigoriadis S, Vonderporten EH, Mamisashvili L, Tomlinson G, Dennis CL, Koren G, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ. 2014;348:f6932.PubMedPubMedCentral

85.

Sadoughi A, Roberts KE, Preston IR, Lai GP, McCollister DH, Farber HW, et al. Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension. Chest. 2013;144:531–41.PubMedPubMedCentral

86.

Jayarajan RN, Shere S, Sutar R, Karmani S, Reddi VS, Kesavan M, et al. Fluoxetine-induced pulmonary hypertension in a patient with schizophrenia. J Neuropsychiatry Clin Neurosci. 2014;26:E12–3.PubMed

87.

Souza R, Humbert M, Sztrymf B, Jaïs X, Yaïci A, Le Pavec J, et al. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J. 2008;31:343–8.PubMed

88.

Baufreton C, Bruneval P, Rousselet MC, Ennezat PV, Fouquet O, Giraud R, et al. Fatal postoperative systemic pulmonary hypertension in benfluorex-induced valvular heart disease surgery: a case report. Medicine. 2017;96:e4985.PubMedPubMedCentral

89.

Szymanski C, Andréjak M, Peltier M, Maréchaux S, Tribouilloy C. Adverse effects of benfluorex on heart valves and pulmonary circulation. Pharmacoepidemiol Drug Saf. 2014;23:679–86.PubMed

90.

Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest. 1997;112:714–21.PubMed

91.

Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122:156–63.PubMed

92.

Bergot E, Sitbon O, Cottin V, Prévot G, Canuet M, Bourdin A, et al. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry. Int J Cardiol. 2014;172:561–7.PubMed

93.

Ceylan ME, Alpsan MH. Pulmonary hypertension during lithium therapy: clinical case study. Psychopharmacol Bull. 2007;40:110–2.PubMed

94.

Zamanian RT, Hedlin H, Greuenwald P, Wilson DM, Segal JI, Jorden M, et al. Features and outcomes of methamphetamine-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2018;197:788–800.PubMedPubMedCentral

95.

Shah NP, Wallis N, Farber HW, Mauro MJ, Wolf RA, Mattei D, et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol. 2015;90:1060–4.PubMed

96.

García-Gutiérrez V, Maestro B, Martinez-Trillo A, Lopez Lorenzo JL, Martin Mateos ML, Alvarez A, et al. Bosutinib appears to be safe, with low cross intolerance, in patients treated in 4th line. Results of the Spanish Compassionate Use Program Blood. 2014;124:5523.

97.

Shepherd J. FDA drug safety podcast for healthcare professionals: Sprycel (dasatinib) and risk of pulmonary arterial hypertension. Available at: http://www.fda.gov/Drugs/DrugSafety/ DrugSafetyPodcasts/ucm275517.htm ().

98.

El-Dabh A, Acharya D. Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors. Pulm Circ. 2019 Jul;5:2045894019865704.

99.

Edahiro Y, Takaku T, Konishi H, Tsukune Y, Fujioka I, Takasu K, et al. Chronic myeloid leukemia complicated by pulmonary hypertension during dasatinib therapy: a single-center retrospective study. Rinsho Ketsueki. 2017;58:2213–8.PubMed

100.

Weatherald J, Chaumais M, Savale L, Jaïs X, Seferian A, Canuet M, et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Respir J. 2017;50(1).PubMed

101.

Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res. 2012;36:e4–6.PubMed

102.

Groeneveldt JA, Gans SJ, Bogaard HJ, Vonk-Noordegraaf A. Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition. Eur Respir J. 2013;42:869–70.PubMed

103.

Weatherald J, Chaumais MC, Montani D. Pulmonary arterial hypertension induced by tyrosine kinase inhibitors. Curr Opin Pulm Med. 2017;23:392–7.PubMed

104.

Nishimori M, Honjo T, Kaihotsu K, Sone N, Yoshikawa S, Imanishi J, et al. Dasatinib-induced pulmonary arterial hypertension treated with upfront combination therapy. Case Rep Cardiol. 2018;2018:3895197.PubMedPubMedCentral

105.

Zakrzewski D, Seferynska I, Warzocha K, Hryniewiecki T. Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia. Int J Hematol. 2012;96:132–5.PubMed

106.

Quilot FM, Georges M, Favrolt N, Beltramo G, Foignot C, Grandvuillemin A, et al. Pulmonary hypertension associated with ponatinib therapy. Eur Respir J. 2016;47:676–9.PubMed

107.

Krishnan U, Mark TM, Niesvizky R, Sobol I. Pulmonary hypertension complicating multiple myeloma. Pulm Circ. 2015;5:590–7.PubMedPubMedCentral

108.

Wang X, Ibrahim YF, Das D, Zungu-Edmondson M, Shults NV, Suzuki YJ. Carfilzomib reverses pulmonary arterial hypertension. Cardiovasc Res. 2016;110:188–99.PubMedPubMedCentral

109.

Tabarroki A, Lindner DJ, Visconte V, Zhang L, Rogers HJ, Parker Y, et al. Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. Leukemia. 2014;28:1486–93.PubMed

110.

Low AT, Howard L, Harrison C, Tulloh RM. Pulmonary arterial hypertension exacerbated by ruxolitinib. Haematologica. 2015;100:e244–5.PubMedPubMedCentral

111.

Govern EM, Judge EP, Kavanagh E, Gaine S, Lynch T. Interferon beta related pulmonary arterial hypertension; an emerging worrying entity? Mult Scler Relat Disord. 2015;4:284–6.PubMed

112.

Savale L, Sattler C, Günther S, Montani D, Chaumais MC, Perrin S, et al. Pulmonary arterial hypertension in patients treated with interferon. Eur Respir J. 2014;44:1627–34.PubMed

113.

Ledinek AH, Jazbec SS, Drinovec I, Rot U. Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report. Mult Scler. 2009;15:885–6.PubMed

114.

George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharm Ther. 2012;135:44–53.

115.

Dhillon S, Kaker A, Dosanjh A, Japra D, Van Thiel DH. Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C. Dig Dis Sci. 2010;55:1785–90.PubMedPubMedCentral

116.

Caravita S, Secchi MB, Wu SC, Pierini S, Paggi A. Sildenafil therapy for interferon-b-1a-induced pulmonary arterial hypertension: a case report. Cardiology. 2011;120:187–9.PubMed

117.

Savale L, Chaumais MC, Montani D, Jaïs X, Hezode C, Antonini TM, et al. Direct-acting antiviral medications for hepatitis C virus infection and pulmonary arterial hypertension. Chest. 2016;150:256–8.PubMed

118.

Traclet J, Khouatra C, Piégay F, Turquier S, Zeghmar S, Mornex JF, et al. Pulmonary arterial hypertension in heroin users. J Heart Lung Transplant. 2016;35:932–4.PubMed

119.

Collazos J, Martínez E, Fernández A, Mayo J. Acute, reversible pulmonary hypertension associated with cocaine use. Respir Med. 1996;90:171–4.PubMed

120.

Meyer LC, Hetem RS, Mitchell D, Fuller A. Hypoxia following etorphine administration in goats (Capra hircus) results more from pulmonary hypertension than from hypoventilation. BMC Vet Res. 2015;11:18.PubMedPubMedCentral

121.

Harter ZJ, Agarwal S, Dalvi P, Voelkel NF, Dhillon NK. Drug abuse and HIV-related pulmonary hypertension: double hit injury. AIDS. 2018;32:2651–67.PubMedPubMedCentral

122.

Degano B, Guillaume M, Savale L, Montani D, Jaïs X, Yaici A, et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS. 2010;24:67–75.PubMed

123.

Perros F, Günther S, Ranchoux B, Godinas L, Antigny F, Chaumais MC, et al. Mitomycin-induced pulmonary veno-occlusive disease: evidence from human disease and animal models. Circulation. 2015;132:834–47.PubMed

124.

Koyama M, Yano T, Kikuchi K, Mizuno M, Nagano N, Hashimoto A, et al. Favorable response to an endothelin receptor antagonist in mitomycin-induced pulmonary veno-occlusive disease with pulmonary capillary hemangiomatosis. Int J Cardiol. 2016;212:245–7.PubMed

125.

Botros L, Van Nieuw Amerongen GP, Vonk Noordegraaf A, Bogaard HJ. Recovery from mitomycin-induced pulmonary arterial hypertension. Ann Am Thorac Soc. 2014;11:468–70.PubMed

126.

Huertas A, Girerd B, Dorfmuller P, O'Callaghan D, Humbert M, Montani D. Pulmonary veno-occlusive disease: advances in clinical management and treatments. Expert Rev Respir Med. 2011;5:217–29.PubMed

127.

Younis TH, Alam A, Paplham P, Spangenthal E, McCarthy P. Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma. Br J Haematol. 2003;121:191–2.PubMed

128.

Ocal A, Kiriş I, Erdinç M, Peker O, Yavuz T, Ibrişim E. Efficiency of prostacyclin in the treatment of protamine-mediated right ventricular failure and acute pulmonary hypertension. Tohoku J Exp Med. 2005;207:51–8.PubMed

129.

Jerath A, Srinivas C, Vegas A, Brister S. The successful management of severe protamine-induced pulmonary hypertension using inhaled prostacyclin. Anesth Analg. 2010;110:365–9.PubMed

130.

Guan Z, Shen X, Zhang YJ, Li XG, Gao YF, Tan J, et al. Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery. Medicine. 2018;97:e10908.PubMedPubMedCentral

131.

Ribeiro Baptista B, Petitpain N, Gomez E, Yelehé-Okouma M, Valentin S, Guillaumot A, et al. Pulmonary arterial hypertension in patient treated for multiple sclerosis with 4-aminopyridine. Fundam Clin Pharmacol. 2019;33:127–9.PubMed

Titel: Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management
verfasst von: Michele Correale
Lucia Tricarico
Davide Grazioli
Ennio Sascia Formica
Rossella Petrucci
Paola Persichella
Matteo Di Biase
Natale Daniele Brunetti
Publikationsdatum: 06.12.2019
Verlag: Springer US
Erschienen in: Cardiovascular Drugs and Therapy / Ausgabe 6/2019
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-019-06920-x

Neu im Fachgebiet Kardiologie

19.04.2024 | Vorhofflimmern | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management

Abstract

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

The Effect of Ranolazine on Glycemic Control: a Narrative Review to Define the Target Population

A Novel Epigenetic Drug-Eluting Balloon Angioplasty Device: Evaluation in a Large Animal Model of Neointimal Hyperplasia

Real-world Comparisons of Direct Oral Anticoagulants for Stroke Prevention in Asian Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis

Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide

Prediabetes with Hypertension and Dyslipidemia: Are They Triad of Future Cardiovascular Risk?

My Last Issue—a Farewell to Cardiovascular Drugs and Therapy

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie